These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22134152)

  • 21. Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial.
    Barlow-Mosha L; Angelidou K; Lindsey J; Archary M; Cotton M; Dittmer S; Fairlie L; Kabugho E; Kamthunzi P; Kinikar A; Mbengeranwa T; Msuya L; Sambo P; Patel K; Barr E; Jean-Phillipe P; Violari A; Mofenson L; Palumbo P; Chi BH
    Clin Infect Dis; 2016 Oct; 63(8):1113-1121. PubMed ID: 27439527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
    Sturt AS; Dokubo EK; Sint TT
    Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment.
    Frohoff C; Moodley M; Fairlie L; Coovadia A; Moultrie H; Kuhn L; Meyers T
    PLoS One; 2011 Feb; 6(2):e17273. PubMed ID: 21383838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients.
    Stanley TL; Joy T; Hadigan CM; Liebau JG; Makimura H; Chen CY; Thomas BJ; Weise SB; Robbins GK; Grinspoon SK
    AIDS; 2009 Jul; 23(11):1349-57. PubMed ID: 19474651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin resistance and lipid profiles in HIV-infected Thai children receiving lopinavir/ritonavir-based highly active antiretroviral therapy.
    Dejkhamron P; Unachak K; Aurpibul L; Sirisanthana V
    J Pediatr Endocrinol Metab; 2014 May; 27(5-6):403-12. PubMed ID: 24259240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.
    van Vonderen MG; Lips P; van Agtmael MA; Hassink EA; Brinkman K; Geerlings SE; Sutinen J; Ristola M; Danner SA; Reiss P
    AIDS; 2009 Jul; 23(11):1367-76. PubMed ID: 19424051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.
    Frange P; Briand N; Avettand-fenoel V; Veber F; Moshous D; Mahlaoui N; Rouzioux C; Blanche S; Chaix ML
    Pediatr Infect Dis J; 2011 Aug; 30(8):684-8. PubMed ID: 21427626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beneficial effects of a switch to a Lopinavir/ritonavir-containing regimen for patients with partial or no immune reconstitution with highly active antiretroviral therapy despite complete viral suppression.
    Pitrak DL; Estes R; Novak RM; Linnares-Diaz M; Tschampa JM
    AIDS Res Hum Retroviruses; 2011 Jun; 27(6):659-67. PubMed ID: 21054216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Virologic failure among children taking lopinavir/ritonavir-containing first-line antiretroviral therapy in South Africa.
    Meyers T; Sawry S; Wong JY; Moultrie H; Pinillos F; Fairlie L; van Zyl G
    Pediatr Infect Dis J; 2015 Feb; 34(2):175-9. PubMed ID: 25741970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.
    Mallolas J; Podzamczer D; Milinkovic A; Domingo P; Clotet B; Ribera E; Gutiérrez F; Knobel H; Cosin J; Ferrer E; Arranz JA; Roca V; Vidal F; Murillas J; Pich J; Pedrol E; Llibre JM; Dalmau D; García I; Aranda M; Cruceta A; Martínez E; Blanco JL; Lazzari Ed; Gatell JM;
    J Acquir Immune Defic Syndr; 2009 May; 51(1):29-36. PubMed ID: 19390327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAzanavir & GLUcose metabolism (ATAGLU) study.
    d'Ettorre G; Ceccarelli G; Zaccarelli M; Ascoli-Bartoli T; Bianchi L; Bellelli V; De Girolamo G; Serafino S; Giustini N; Mastroianni CM; Vullo V
    Int J STD AIDS; 2016 Jul; 27(8):638-43. PubMed ID: 26068963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study.
    Ofotokun I; Sheth AN; Sanford SE; Easley KA; Shenvi N; White K; Eaton ME; Del Rio C; Lennox JL
    AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1196-206. PubMed ID: 22364141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis.
    Menshawy A; Ismail A; Abushouk AI; Ahmed H; Menshawy E; Elmaraezy A; Gadelkarim M; Abdel-Maboud M; Attia A; Negida A
    Arch Virol; 2017 Aug; 162(8):2181-2190. PubMed ID: 28361290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial.
    Kuhn L; Coovadia A; Strehlau R; Martens L; Hu CC; Meyers T; Sherman G; Hunt G; Persaud D; Morris L; Tsai WY; Abrams EJ
    Lancet Infect Dis; 2012 Jul; 12(7):521-30. PubMed ID: 22424722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.
    Behrens G; Maserati R; Rieger A; Domingo P; Abel F; Wang H; Pearce G
    Antivir Ther; 2012; 17(6):1011-20. PubMed ID: 22910324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell/mm3 in Mexico.
    Sierra-Madero J; Villasis-Keever A; Méndez P; Mosqueda-Gómez JL; Torres-Escobar I; Gutiérrez-Escolano F; Juárez-Kasusky I; Magana-Aquino M; Ramos-Santos C; Pérez-Saleme L; Rangel-Frausto S; Antuna-Puente B; Soto-Ramírez LE; Lima V; Belaunzarán-Zamudio F; Crabtree-Ramírez B; Montaner J
    J Acquir Immune Defic Syndr; 2010 Apr; 53(5):582-8. PubMed ID: 20090545
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavir.
    Rojas J; Lonca M; Imaz A; Estrada V; Asensi V; Miralles C; Domingo P; Montero M; del Rio L; Fontdevila J; Perez I; Cruceta A; Gatell JM; Arnedo M; Martínez E
    HIV Med; 2016 May; 17(5):340-9. PubMed ID: 27089862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
    Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
    AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.